We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Chinese Expert Consensus on Management of Special Adverse Effects Associated with Lorlatinib.
- Authors
Qing ZHOU; Shun LU; Yong LI; Fujun JIA; Guanjun LI; Zhen HONG; You LU; Yun FAN; Jianying ZHOU; Zhe LIU; Juan LI; Yi-Long WU
- Abstract
Anaplastic lymphoma kinase (ALK) fusions represent the second most common oncogenic driver mutation in non-small cell lung cancer (NSCLC). As the new class of 3rd generation of ALK tyrosine kinase inhibitor (TKI), lorlatinib has shown robust potency and brain-penetrant clinical activity against a wide spectrum of multiple resistance mutations within the ALK domain detected during crizotinib and 2nd generation ALK TKI treatment. Lorlatinib is generally well-tolerated with unique adverse drug reaction/adverse event, including hyperlipidemia and central nervous system effects, which are mostly mild to moderate severity and manageable through dosage modifications and/or standard medical intervention. For advanced NSCLC with ALK positivity, patients should be evaluated for baseline characteristics and pre-existing medication, informed of the potential toxicities, and periodically monitored to balance benefits and risks. Moreover, a multidisciplinary group of experts is essential to establish a comprehensive diagnostic and therapeutic strategy.
- Subjects
PREVENTION of drug side effects; CONSENSUS (Social sciences); LUNG cancer; DRUG tolerance; PROTEIN-tyrosine kinase inhibitors; ANAPLASTIC lymphoma kinase; HYPERLIPIDEMIA
- Publication
Chinese Journal of Lung Cancer, 2022, Vol 25, Issue 8, p555
- ISSN
1009-3419
- Publication type
Article
- DOI
10.3779/j.issn.1009-3419.2022.101.39